Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
1.
Cell Res ; 29(10): 846-861, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31481761

RESUMEN

PD-1 blockade represents a major therapeutic avenue in anticancer immunotherapy. Delineating mechanisms of secondary resistance to this strategy is increasingly important. Here, we identified the deleterious role of signaling via the type I interferon (IFN) receptor in tumor and antigen presenting cells, that induced the expression of nitric oxide synthase 2 (NOS2), associated with intratumor accumulation of regulatory T cells (Treg) and myeloid cells and acquired resistance to anti-PD-1 monoclonal antibody (mAb). Sustained IFNß transcription was observed in resistant tumors, in turn inducing PD-L1 and NOS2 expression in both tumor and dendritic cells (DC). Whereas PD-L1 was not involved in secondary resistance to anti-PD-1 mAb, pharmacological or genetic inhibition of NOS2 maintained long-term control of tumors by PD-1 blockade, through reduction of Treg and DC activation. Resistance to immunotherapies, including anti-PD-1 mAb in melanoma patients, was also correlated with the induction of a type I IFN signature. Hence, the role of type I IFN in response to PD-1 blockade should be revisited as sustained type I IFN signaling may contribute to resistance to therapy.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Interferón Tipo I/metabolismo , Receptor de Muerte Celular Programada 1/inmunología , Transducción de Señal/efectos de los fármacos , Animales , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/uso terapéutico , Antígeno B7-H1/metabolismo , Línea Celular Tumoral , Células Dendríticas/citología , Células Dendríticas/metabolismo , Resistencia a Antineoplásicos , Humanos , Estimación de Kaplan-Meier , Melanoma/tratamiento farmacológico , Melanoma/mortalidad , Melanoma/patología , Ratones , Ratones Endogámicos C57BL , Neoplasias/tratamiento farmacológico , Neoplasias/mortalidad , Neoplasias/patología , Óxido Nítrico Sintasa de Tipo II/metabolismo , Linfocitos T Reguladores/citología , Linfocitos T Reguladores/inmunología , Linfocitos T Reguladores/metabolismo
2.
Aging (Albany NY) ; 11(11): 3418-3431, 2019 06 07.
Artículo en Inglés | MEDLINE | ID: mdl-31173576

RESUMEN

The metabolite α-ketoglutarate is membrane-impermeable, meaning that it is usually added to cells in the form of esters such as dimethyl -ketoglutarate (DMKG), trifluoromethylbenzyl α-ketoglutarate (TFMKG) and octyl α-ketoglutarate (O-KG). Once these compounds cross the plasma membrane, they are hydrolyzed by esterases to generate α-ketoglutarate, which remains trapped within cells. Here, we systematically compared DMKG, TFMKG and O-KG for their metabolic and functional effects. All three compounds similarly increased the intracellular levels of α-ketoglutarate, yet each of them had multiple effects on other metabolites that were not shared among the three agents, as determined by mass spectrometric metabolomics. While all three compounds reduced autophagy induced by culture in nutrient-free conditions, TFMKG and O-KG (but not DMKG) caused an increase in baseline autophagy in cells cultured in complete medium. O-KG (but neither DMKG nor TFMK) inhibited oxidative phosphorylation and exhibited cellular toxicity. Altogether, these results support the idea that intracellular α-ketoglutarate inhibits starvation-induced autophagy and that it has no direct respiration-inhibitory effect.


Asunto(s)
Autofagia/efectos de los fármacos , Ácidos Cetoglutáricos/metabolismo , Autofagia/fisiología , Línea Celular Tumoral , Humanos , Ácidos Cetoglutáricos/farmacología , Espectrometría de Masas , Fosforilación Oxidativa/efectos de los fármacos
3.
Nat Commun ; 10(1): 651, 2019 02 19.
Artículo en Inglés | MEDLINE | ID: mdl-30783116

RESUMEN

Ageing constitutes the most important risk factor for all major chronic ailments, including malignant, cardiovascular and neurodegenerative diseases. However, behavioural and pharmacological interventions with feasible potential to promote health upon ageing remain rare. Here we report the identification of the flavonoid 4,4'-dimethoxychalcone (DMC) as a natural compound with anti-ageing properties. External DMC administration extends the lifespan of yeast, worms and flies, decelerates senescence of human cell cultures, and protects mice from prolonged myocardial ischaemia. Concomitantly, DMC induces autophagy, which is essential for its cytoprotective effects from yeast to mice. This pro-autophagic response induces a conserved systemic change in metabolism, operates independently of TORC1 signalling and depends on specific GATA transcription factors. Notably, we identify DMC in the plant Angelica keiskei koidzumi, to which longevity- and health-promoting effects are ascribed in Asian traditional medicine. In summary, we have identified and mechanistically characterised the conserved longevity-promoting effects of a natural anti-ageing drug.


Asunto(s)
Envejecimiento/efectos de los fármacos , Autofagia/efectos de los fármacos , Flavonoides/farmacología , Longevidad/efectos de los fármacos , Envejecimiento/fisiología , Angelica/química , Animales , Caenorhabditis elegans/efectos de los fármacos , Proteínas de Transporte de Catión/genética , Muerte Celular/efectos de los fármacos , Línea Celular/efectos de los fármacos , Drosophila melanogaster/efectos de los fármacos , Flavonoides/administración & dosificación , Factores de Transcripción GATA/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Longevidad/fisiología , Masculino , Diana Mecanicista del Complejo 1 de la Rapamicina/metabolismo , Medicina Tradicional de Asia Oriental , Ratones , Ratones Endogámicos C57BL , Isquemia Miocárdica/tratamiento farmacológico , Extractos Vegetales/farmacología , Saccharomyces cerevisiae/efectos de los fármacos , Saccharomyces cerevisiae/metabolismo , Proteínas de Saccharomyces cerevisiae/genética , Transducción de Señal , Sirolimus/farmacología , Factores de Transcripción/efectos de los fármacos , Factores de Transcripción/genética
4.
Oncoimmunology ; 7(9): e1462431, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30228932

RESUMEN

The analysis of tumor growth curves is standard practice in experimental oncology including tumor immunology. In experimental oncology, cancer cells are inoculated into rodents (mostly mice) and their growth is monitored by measuring tumor diameter, surface or volume over time as a function of distinct treatments. Then, different groups of tumors/treatments are compared among each other for their evolution and possible responses to treatment. The R package TumGrowth has been created as a software tool allowing to carry out a series of statistical comparisons across or between groups of tumor growth curves obtained in a standard laboratory, for experimenters with limited knowledge in statistics. TumGrowth is freely available online at https://kroemerlab.shinyapps.io/TumGrowth/ and can be downloaded into any computer. It offers an exhaustive panoply of tools to visualize and analyze complex data sets including longitudinal, cross-sectional and time-to-endpoint measurements.

5.
Cell Rep ; 22(9): 2395-2407, 2018 02 27.
Artículo en Inglés | MEDLINE | ID: mdl-29490275

RESUMEN

The age-associated deterioration in cellular and organismal functions associates with dysregulation of nutrient-sensing pathways and disabled autophagy. The reactivation of autophagic flux may prevent or ameliorate age-related metabolic dysfunctions. Non-toxic compounds endowed with the capacity to reduce the overall levels of protein acetylation and to induce autophagy have been categorized as caloric restriction mimetics (CRMs). Here, we show that aspirin or its active metabolite salicylate induce autophagy by virtue of their capacity to inhibit the acetyltransferase activity of EP300. While salicylate readily stimulates autophagic flux in control cells, it fails to further increase autophagy levels in EP300-deficient cells, as well as in cells in which endogenous EP300 has been replaced by salicylate-resistant EP300 mutants. Accordingly, the pro-autophagic activity of aspirin and salicylate on the nematode Caenorhabditis elegans is lost when the expression of the EP300 ortholog cpb-1 is reduced. Altogether, these findings identify aspirin as an evolutionary conserved CRM.


Asunto(s)
Aspirina/farmacología , Restricción Calórica , Acetilcoenzima A/metabolismo , Animales , Autofagia/efectos de los fármacos , Autofagia/genética , Línea Celular Tumoral , Proteína p300 Asociada a E1A/metabolismo , Humanos , Metaboloma/efectos de los fármacos , Metabolómica , Ratones Endogámicos C57BL
6.
Oncoimmunology ; 6(8): e1299303, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28919986

RESUMEN

Existing clinical, anatomopathological and molecular biomarkers fail to reliably predict the prognosis of cutaneous melanoma. Biomarkers for determining which patients receive adjuvant therapies are needed. The emergence of new technologies and the discovery of new immune populations with different prognostic values allow the immune network in the tumor to be better understood. Importantly, new molecules identified and expressed by immune cells have been shown to reduce the antitumor immune efficacy of therapies, prompting researchers to develop antibodies targeting these so-called "immune checkpoints", which have now entered the oncotherapeutic armamentarium.

8.
Cancer Cell ; 30(1): 147-160, 2016 07 11.
Artículo en Inglés | MEDLINE | ID: mdl-27411589

RESUMEN

Caloric restriction mimetics (CRMs) mimic the biochemical effects of nutrient deprivation by reducing lysine acetylation of cellular proteins, thus triggering autophagy. Treatment with the CRM hydroxycitrate, an inhibitor of ATP citrate lyase, induced the depletion of regulatory T cells (which dampen anticancer immunity) from autophagy-competent, but not autophagy-deficient, mutant KRAS-induced lung cancers in mice, thereby improving anticancer immunosurveillance and reducing tumor mass. Short-term fasting or treatment with several chemically unrelated autophagy-inducing CRMs, including hydroxycitrate and spermidine, improved the inhibition of tumor growth by chemotherapy in vivo. This effect was only observed for autophagy-competent tumors, depended on the presence of T lymphocytes, and was accompanied by the depletion of regulatory T cells from the tumor bed.


Asunto(s)
Citratos/administración & dosificación , Neoplasias Experimentales/dietoterapia , Neoplasias Experimentales/tratamiento farmacológico , Espermidina/administración & dosificación , Linfocitos T Reguladores/efectos de los fármacos , Animales , Autofagia , Proteína 5 Relacionada con la Autofagia/genética , Restricción Calórica/métodos , Línea Celular Tumoral , Citratos/farmacología , Humanos , Metotrexato/administración & dosificación , Metotrexato/farmacología , Ratones , Monitorización Inmunológica , Mutación , Trasplante de Neoplasias , Neoplasias Experimentales/inmunología , Proteínas Proto-Oncogénicas p21(ras)/genética , Espermidina/farmacología
9.
Cancer Res ; 76(11): 3122-6, 2016 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-27197163

RESUMEN

Pattern recognition receptors allow the innate immune system to perceive the presence of microbial products and to launch the first steps of the defense response. Some pattern recognition receptors also sense endogenous ligands that are released from uninfected dying cells, thereby activating immune responses against dead-cell antigens. This applies to toll-like receptors 3 and 4 (TLR3, TLR4), which sense double-stranded RNA and high-mobility group protein B1 (HMGB1), respectively, as well as to formyl peptide receptor-1 (FPR1), which interacts with Annexin A1 (ANXA1) from dead cells. Breast cancer patients who bear loss-of-function alleles in TLR3, TLR4, and FPR1 exhibit a reduced metastasis-free and overall survival after treatment with anthracycline-based adjuvant chemotherapy. These genetic defects are epistatic with respect to each other, suggesting that they act on the same pathway, linking chemotherapy to a therapeutically relevant anticancer immune response. Loss-of-function alleles in TLR4 and FPR1 also affect the prognosis of colorectal cancer patients treated with oxaliplatin-based chemotherapy. Altogether, these results support the idea that conventional anticancer treatments rely on stimulation of anticancer immune responses to become fully efficient. Cancer Res; 76(11); 3122-6. ©2016 AACR.


Asunto(s)
Neoplasias de la Mama/patología , Receptores de Reconocimiento de Patrones/metabolismo , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , Quimioterapia Adyuvante , Femenino , Humanos , Pronóstico
10.
J Invest Dermatol ; 136(5): 994-1001, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-26829031

RESUMEN

Stage III metastatic melanomas require adequate adjuvant immunotherapy to prevent relapses. Prognostic factors are awaited to optimize the clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAF(V600) activating mutation have clinical significance. Based on a comprehensive immunophenotyping of 252 parameters per patient in paired blood and metastatic lymph nodes performed in 39 metastatic melanomas, we found that blood markers were as contributive as tumor-infiltrated lymphocyte immunotypes, and parameters associated with lymphocyte exhaustion/suppression showed higher clinical significance than those related to activation or lineage. High frequencies of CD45RA(+)CD4(+) and CD3(-)CD56(-) tumor-infiltrated lymphocytes appear to be independent prognostic factors of short progression-free survival. High NKG2D expression on CD8(+)tumor-infiltrated lymphocytes, low level of regulatory T-cell tumor-infiltrated lymphocytes, and low PD-L1 expression on circulating T cells were retained in the multivariate Cox analysis model to predict prolonged overall survival. Prospective studies are needed to determine whether such immunological markers may guide adjuvant therapies in stage III metastatic melanomas.


Asunto(s)
Ganglios Linfáticos/patología , Melanoma/mortalidad , Melanoma/patología , Recurrencia Local de Neoplasia/prevención & control , Neoplasias Cutáneas/mortalidad , Neoplasias Cutáneas/patología , Adulto , Estudios de Cohortes , Terapia Combinada , Supervivencia sin Enfermedad , Femenino , Humanos , Inmunofenotipificación , Inmunoterapia/métodos , Masculino , Melanoma/terapia , Persona de Mediana Edad , Terapia Neoadyuvante/métodos , Invasividad Neoplásica/patología , Recurrencia Local de Neoplasia/mortalidad , Pronóstico , Estudios Prospectivos , Medición de Riesgo , Neoplasias Cutáneas/terapia , Análisis de Supervivencia , Melanoma Cutáneo Maligno
11.
J Clin Invest ; 126(3): 921-37, 2016 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-26854930

RESUMEN

Melanoma prognosis is dictated by tumor-infiltrating lymphocytes, the migratory and functional behavior of which is guided by chemokine or cytokine gradients. Here, we retrospectively analyzed the expression patterns of 9 homing receptors (CCR/CXCR) in naive and memory CD4+ and CD8+ T lymphocytes in 57 patients with metastatic melanoma (MMel) with various sites of metastases to evaluate whether T cell CCR/CXCR expression correlates with intratumoral accumulation, metastatic progression, and/or overall survival (OS). Homing receptor expression on lymphocytes strongly correlated with MMel dissemination. Loss of CCR6 or CXCR3, but not cutaneous lymphocyte antigen (CLA), on circulating T cell subsets was associated with skin or lymph node metastases, loss of CXCR4, CXCR5, and CCR9 corresponded with lung involvement, and a rise in CCR10 or CD103 was associated with widespread dissemination. High frequencies of CD8+CCR9+ naive T cells correlated with prolonged OS, while neutralizing the CCR9/CCL25 axis in mice stimulated tumor progression. The expansion of CLA-expressing effector memory CD8+ T cells in response to a single administration of CTLA4 blockade predicted disease control at 3 months in 47 patients with MMel. Thus, specific CCR/CXCR expression patterns on circulating T lymphocytes may guide potential diagnostic and therapeutic approaches.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Neoplasias Pulmonares/metabolismo , Melanoma/metabolismo , Receptores de Quimiocina/metabolismo , Neoplasias Cutáneas/metabolismo , Linfocitos T/metabolismo , Adulto , Animales , Anticuerpos Monoclonales/farmacología , Antineoplásicos/farmacología , Estudios de Casos y Controles , Línea Celular Tumoral , Femenino , Humanos , Ipilimumab , Estimación de Kaplan-Meier , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/secundario , Metástasis Linfática , Masculino , Melanoma/inmunología , Melanoma/mortalidad , Melanoma/secundario , Ratones Endogámicos C57BL , Persona de Mediana Edad , Trasplante de Neoplasias , Modelos de Riesgos Proporcionales , Curva ROC , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/mortalidad , Neoplasias Cutáneas/patología
12.
Science ; 350(6264): 1079-84, 2015 Nov 27.
Artículo en Inglés | MEDLINE | ID: mdl-26541610

RESUMEN

Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis-specific T cells. Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Bacteroides/inmunología , Antígeno CTLA-4/antagonistas & inhibidores , Microbioma Gastrointestinal/inmunología , Melanoma/terapia , Neoplasias Cutáneas/terapia , Adulto , Anciano , Anciano de 80 o más Años , Animales , Antibacterianos/farmacología , Anticuerpos Monoclonales/efectos adversos , Antígeno CTLA-4/inmunología , Disbiosis/inmunología , Trasplante de Microbiota Fecal , Femenino , Microbioma Gastrointestinal/efectos de los fármacos , Vida Libre de Gérmenes/inmunología , Humanos , Memoria Inmunológica , Inmunoterapia , Intestinos/inmunología , Intestinos/microbiología , Ipilimumab , Masculino , Ratones , Ratones Endogámicos C57BL , Persona de Mediana Edad , Linfocitos T/inmunología
13.
Science ; 350(6263): 972-8, 2015 Nov 20.
Artículo en Inglés | MEDLINE | ID: mdl-26516201

RESUMEN

Antitumor immunity driven by intratumoral dendritic cells contributes to the efficacy of anthracycline-based chemotherapy in cancer. We identified a loss-of-function allele of the gene coding for formyl peptide receptor 1 (FPR1) that was associated with poor metastasis-free and overall survival in breast and colorectal cancer patients receiving adjuvant chemotherapy. The therapeutic effects of anthracyclines were abrogated in tumor-bearing Fpr1(-/-) mice due to impaired antitumor immunity. Fpr1-deficient dendritic cells failed to approach dying cancer cells and, as a result, could not elicit antitumor T cell immunity. Experiments performed in a microfluidic device confirmed that FPR1 and its ligand, annexin-1, promoted stable interactions between dying cancer cells and human or murine leukocytes. Altogether, these results highlight the importance of FPR1 in chemotherapy-induced anticancer immune responses.


Asunto(s)
Antraciclinas/uso terapéutico , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Receptores de Formil Péptido/fisiología , Alelos , Animales , Anexina A1/metabolismo , Anexina A1/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/inmunología , Línea Celular Tumoral , Quimioterapia Adyuvante , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/inmunología , Células Dendríticas/efectos de los fármacos , Células Dendríticas/inmunología , Femenino , Humanos , Inmunidad Innata/genética , Leucocitos/efectos de los fármacos , Leucocitos/inmunología , Ratones , Polimorfismo de Nucleótido Simple , Receptores de Formil Péptido/genética , Linfocitos T/inmunología
14.
Oncotarget ; 6(25): 20840-50, 2015 Aug 28.
Artículo en Inglés | MEDLINE | ID: mdl-26369701

RESUMEN

Ever accumulating evidence indicates that the long-term effects of radiotherapy and chemotherapy largely depend on the induction (or restoration) of an anticancer immune response. Here, we investigated this paradigm in the context of esophageal carcinomas treated by neo-adjuvant radiochemotherapy, in a cohort encompassing 196 patients. We found that the density of the FOXP3+ regulatory T cell (Treg) infiltrate present in the residual tumor (or its scar) correlated with the pathological response (the less Tregs the more pronounced was the histological response) and predicted cancer-specific survival. In contrast, there was no significant clinical impact of the frequency of CD8+ cytotoxic T cells. At difference with breast or colorectal cancer, a loss-of-function allele of toll like receptor 4 (TLR4) improved cancer-specific survival of patients with esophageal cancer. While a loss-of-function allele of purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7) failed to affect cancer-specific survival, its presence did correlate with an increase in Treg infiltration. Altogether, these results corroborate the notion that the immunosurveillance seals the fate of patients with esophageal carcinomas treated with conventional radiochemotherapy.


Asunto(s)
Quimioradioterapia/métodos , Neoplasias Esofágicas/inmunología , Linfocitos Infiltrantes de Tumor/inmunología , Linfocitos T Reguladores/citología , Alelos , Apoptosis , Linfocitos T CD8-positivos/citología , Estudios de Cohortes , Neoplasias Esofágicas/tratamiento farmacológico , Neoplasias Esofágicas/radioterapia , Femenino , Factores de Transcripción Forkhead/metabolismo , Regulación Neoplásica de la Expresión Génica , Genotipo , Humanos , Inmunohistoquímica , Masculino , Pronóstico , Receptores Purinérgicos P2X7/metabolismo , Receptor Toll-Like 4/metabolismo , Resultado del Tratamiento
15.
Cell Cycle ; 14(15): 2399-407, 2015 Aug 03.
Artículo en Inglés | MEDLINE | ID: mdl-26098646

RESUMEN

Recently, we reported that saturated and unsaturated fatty acids trigger autophagy through distinct signal transduction pathways. Saturated fatty acids like palmitate (PA) induce autophagic responses that rely on phosphatidylinositol 3-kinase, catalytic subunit type 3 (PIK3C3, best known as VPS34) and beclin 1 (BECN1). Conversely, unsaturated fatty acids like oleate (OL) promote non-canonical, PIK3C3- and BECN1-independent autophagy. Here, we explored the metabolic effects of autophagy-inducing doses of PA and OL in mice. Mass spectrometry coupled to principal component analysis revealed that PA and OL induce well distinguishable changes in circulating metabolites as well as in the metabolic profile of the liver, heart, and skeletal muscle. Importantly, PA (but not OL) causes the depletion of multiple autophagy-inhibitory amino acids in the liver. Conversely, OL (but not PA) increased the hepatic levels of nicotinamide adenine dinucleotide (NAD), an obligate co-factor for autophagy-stimulatory enzymes of the sirtuin family. Moreover, PA (but not OL) raised the concentrations of acyl-carnitines in the heart, a phenomenon that perhaps is linked to its cardiotoxicity. PA also depleted the liver from spermine and spermidine, 2 polyamines have been ascribed with lifespan-extending activity. The metabolic changes imposed by unsaturated and saturated fatty acids may contribute to their health-promoting and health-deteriorating effects, respectively.


Asunto(s)
Envejecimiento/fisiología , Autofagia/fisiología , Ácido Oléico/metabolismo , Palmitatos/metabolismo , Aminoácidos/metabolismo , Animales , Femenino , Hígado/metabolismo , Espectrometría de Masas , Metabolómica , Ratones , Ratones Endogámicos C57BL , Músculo Esquelético/metabolismo , Miocardio/metabolismo , NAD/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Análisis de Componente Principal , Transducción de Señal/efectos de los fármacos , Espermidina/metabolismo , Espermina/metabolismo
16.
Nat Med ; 20(11): 1301-9, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25344738

RESUMEN

Some of the anti-neoplastic effects of anthracyclines in mice originate from the induction of innate and T cell-mediated anticancer immune responses. Here we demonstrate that anthracyclines stimulate the rapid production of type I interferons (IFNs) by malignant cells after activation of the endosomal pattern recognition receptor Toll-like receptor 3 (TLR3). By binding to IFN-α and IFN-ß receptors (IFNARs) on neoplastic cells, type I IFNs trigger autocrine and paracrine circuitries that result in the release of chemokine (C-X-C motif) ligand 10 (CXCL10). Tumors lacking Tlr3 or Ifnar failed to respond to chemotherapy unless type I IFN or Cxcl10, respectively, was artificially supplied. Moreover, a type I IFN-related signature predicted clinical responses to anthracycline-based chemotherapy in several independent cohorts of patients with breast carcinoma characterized by poor prognosis. Our data suggest that anthracycline-mediated immune responses mimic those induced by viral pathogens. We surmise that such 'viral mimicry' constitutes a hallmark of successful chemotherapy.


Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Doxorrubicina/uso terapéutico , Interferón Tipo I/metabolismo , Transducción de Señal , Proteínas Adaptadoras del Transporte Vesicular/metabolismo , Animales , Antraciclinas/farmacología , Antraciclinas/uso terapéutico , Neoplasias de la Mama/genética , Neoplasias de la Mama/inmunología , Quimiocina CXCL10/metabolismo , Doxorrubicina/farmacología , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Inmunocompetencia/efectos de los fármacos , Interferón Tipo I/biosíntesis , Ratones Endogámicos C57BL , Proteínas de Resistencia a Mixovirus/metabolismo , Terapia Neoadyuvante , Metástasis de la Neoplasia , ARN/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptor de Interferón alfa y beta/metabolismo , Receptores de Reconocimiento de Patrones/metabolismo , Transducción de Señal/efectos de los fármacos , Receptor Toll-Like 3/metabolismo , Resultado del Tratamiento
17.
Mol Cell ; 53(5): 710-25, 2014 Mar 06.
Artículo en Inglés | MEDLINE | ID: mdl-24560926

RESUMEN

Acetyl-coenzyme A (AcCoA) is a major integrator of the nutritional status at the crossroads of fat, sugar, and protein catabolism. Here we show that nutrient starvation causes rapid depletion of AcCoA. AcCoA depletion entailed the commensurate reduction in the overall acetylation of cytoplasmic proteins, as well as the induction of autophagy, a homeostatic process of self-digestion. Multiple distinct manipulations designed to increase or reduce cytosolic AcCoA led to the suppression or induction of autophagy, respectively, both in cultured human cells and in mice. Moreover, maintenance of high AcCoA levels inhibited maladaptive autophagy in a model of cardiac pressure overload. Depletion of AcCoA reduced the activity of the acetyltransferase EP300, and EP300 was required for the suppression of autophagy by high AcCoA levels. Altogether, our results indicate that cytosolic AcCoA functions as a central metabolic regulator of autophagy, thus delineating AcCoA-centered pharmacological strategies that allow for the therapeutic manipulation of autophagy.


Asunto(s)
Acetilcoenzima A/química , Autofagia , Citosol/enzimología , Regulación Enzimológica de la Expresión Génica , Adenosina Trifosfato/química , Animales , Línea Celular Tumoral , Núcleo Celular/metabolismo , Citoplasma/metabolismo , Citosol/metabolismo , Proteína p300 Asociada a E1A/química , Proteínas Fluorescentes Verdes/metabolismo , Células HCT116 , Células HeLa , Humanos , Ácidos Cetoglutáricos/química , Ratones , Ratones Endogámicos C57BL , Microscopía Fluorescente , Mitocondrias/metabolismo , ARN Interferente Pequeño/metabolismo
18.
Science ; 342(6161): 971-6, 2013 Nov 22.
Artículo en Inglés | MEDLINE | ID: mdl-24264990

RESUMEN

Cyclophosphamide is one of several clinically important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses. Studying mouse models, we demonstrate that cyclophosphamide alters the composition of microbiota in the small intestine and induces the translocation of selected species of Gram-positive bacteria into secondary lymphoid organs. There, these bacteria stimulate the generation of a specific subset of "pathogenic" T helper 17 (pT(H)17) cells and memory T(H)1 immune responses. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram-positive bacteria showed a reduction in pT(H)17 responses, and their tumors were resistant to cyclophosphamide. Adoptive transfer of pT(H)17 cells partially restored the antitumor efficacy of cyclophosphamide. These results suggest that the gut microbiota help shape the anticancer immune response.


Asunto(s)
Antineoplásicos/uso terapéutico , Traslocación Bacteriana/efectos de los fármacos , Ciclofosfamida/uso terapéutico , Inmunosupresores/uso terapéutico , Intestino Delgado/microbiología , Microbiota/fisiología , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Traslado Adoptivo , Animales , Antibacterianos/administración & dosificación , Vida Libre de Gérmenes , Bacterias Grampositivas/efectos de los fármacos , Bacterias Grampositivas/fisiología , Memoria Inmunológica , Tejido Linfoide/inmunología , Tejido Linfoide/microbiología , Ratones , Microbiota/efectos de los fármacos , Células Th17/inmunología , Células Th17/trasplante
19.
Cell Cycle ; 12(6): 877-83, 2013 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-23428903

RESUMEN

The antineoplastic agent cis-diammineplatinum(II) dichloride (cisplatin, CDDP) is part of the poorly effective standard treatment of non-small cell lung carcinoma (NSCLC). Here, we report a novel strategy to improve the efficacy of CDDP. In conditions in which CDDP alone or either of two PARP inhibitors, PJ34 hydrochloride hydrate or CEP 8983, used as standalone treatments were inefficient in killing NSCLC cells, the combination of CDDP plus PJ34 or that of CDDP plus CEP 8983 were found to kill a substantial fraction of the cells. This cytotoxic synergy could be recapitulated by combining CDDP and the siRNA-mediated depletion of the principal PARP isoform, PARP1, indicating that it is mediated by on-target effects of PJ34 or CEP 8983. CDDP and PARP inhibitors synergized in inducing DNA damage foci, mitochondrial membrane permeabilization leading to cytochrome c release, and dissipation of the inner transmembrane potential, caspase activation, plasma membrane rupture and loss of clonogenic potential in NSCLC cells. Collectively, our results indicate that CDDP can be advantageously combined with PARP inhibitors to kill several NSCLC cell lines, independently from their p53 status. Combined treatment with CDDP and PARP inhibitors elicits the intrinsic pathway of apoptosis.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Cisplatino/farmacología , Inhibidores Enzimáticos/farmacología , Neoplasias Pulmonares/tratamiento farmacológico , Inhibidores de Poli(ADP-Ribosa) Polimerasas , Antineoplásicos/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Apoptosis/efectos de los fármacos , Carbazoles/farmacología , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Línea Celular Tumoral , Membrana Celular/efectos de los fármacos , Citocromos c/metabolismo , Daño del ADN/efectos de los fármacos , Sinergismo Farmacológico , Humanos , Neoplasias Pulmonares/metabolismo , Membranas Mitocondriales/efectos de los fármacos , Fenantrenos/farmacología , Ftalimidas/farmacología , Poli(ADP-Ribosa) Polimerasa-1 , Poli(ADP-Ribosa) Polimerasas/genética , Interferencia de ARN , ARN Interferente Pequeño
20.
PLoS One ; 7(7): e41156, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22829922

RESUMEN

BACKGROUND & AIMS: Liver is a target organ in many mitochondrial disorders, especially if the complex III assembly factor BCS1L is mutated. To reveal disease mechanism due to such mutations, we have produced a transgenic mouse model with c.232A>G mutation in Bcs1l, the causative mutation for GRACILE syndrome. The homozygous mice develop mitochondrial hepatopathy with steatosis and fibrosis after weaning. Our aim was to assess cellular mechanisms for disease onset and progression using metabolomics. METHODS: With mass spectrometry we analyzed metabolite patterns in liver samples obtained from homozygotes and littermate controls of three ages. As oxidative stress might be a mechanism for mitochondrial hepatopathy, we also assessed H(2)O(2) production and expression of antioxidants. RESULTS: Homozygotes had a similar metabolic profile at 14 days of age as controls, with the exception of slightly decreased AMP. At 24 days, when hepatocytes display first histopathological signs, increases in succinate, fumarate and AMP were found associated with impaired glucose turnover and beta-oxidation. At end stage disease after 30 days, these changes were pronounced with decreased carbohydrates, high levels of acylcarnitines and amino acids, and elevated biogenic amines, especially putrescine. Signs of oxidative stress were present in end-stage disease. CONCLUSIONS: The findings suggest an early Krebs cycle defect with increases of its intermediates, which might play a role in disease onset. During disease progression, carbohydrate and fatty acid metabolism deteriorate leading to a starvation-like condition. The mouse model is valuable for further investigations on mechanisms in mitochondrial hepatopathy and for interventions.


Asunto(s)
Complejo III de Transporte de Electrones/deficiencia , Hígado/metabolismo , Chaperonas Moleculares/genética , ATPasas Asociadas con Actividades Celulares Diversas , Adenosina Monofosfato/metabolismo , Animales , Antioxidantes/metabolismo , Complejo III de Transporte de Electrones/genética , Fumaratos/metabolismo , Peróxido de Hidrógeno/metabolismo , Espectrometría de Masas , Ratones , Enfermedades Mitocondriales/genética , Enfermedades Mitocondriales/metabolismo , Mutación , Estrés Oxidativo/genética , Estrés Oxidativo/fisiología , Ácido Succínico/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...